Drug discovery

Financial pressures stretching Lilly

October 7, 2013
J.K. Wall
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
More

Lilly, other drugmakers itching to find new psoriasis treatment

October 4, 2013
Bloomberg News
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
More

Lilly shares dip after cancer treatment misses goal

September 26, 2013
Associated Press
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
More

Lilly lung cancer drug raises patient survival in trial

August 13, 2013
Bloomberg News
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
More

Lilly aims potential Alzheimer’s drug at early patients

July 12, 2013
Bloomberg News
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Drugmakers may face ‘pay for delay’ suits, high court rules

June 18, 2013
Bloomberg News
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
More

Lilly to take over development of diabetes drug

June 17, 2013
Associated Press
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
More

Lilly suing J&J for patent rights in Alzheimer's drug race

April 25, 2013
Bloomberg News
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
More

IU medical school's push to launch startups bears fruitRestricted Content

April 13, 2013
J.K. Wall
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
More

J&J wins OK for first in new class of diabetes drugs

March 31, 2013
Bloomberg News
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
More

Lilly, Boehringer submit diabetes drug to FDA

March 25, 2013
Associated Press
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
More

Court may decide if drugmakers can pay to delay generics

March 25, 2013
Associated Press
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
More

Profits at center of biosimilars debate

March 18, 2013
J.K. Wall
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
More

Q&A

March 11, 2013
J.K. Wall
Mike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
More

Endocyte stock sinks due to possible drug-filing delay

February 26, 2013
J.K. Wall
Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer drug could be delayed another 10 months.
More

Lilly halts late-stage testing of rheumatoid arthritis drug

February 7, 2013
Bloomberg News
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
More

Lilly aims to submit five new drugs for approval

February 4, 2013
J.K. Wall
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
More

Once-thriving drug lab in turnaround modeRestricted Content

January 26, 2013
J.K. Wall
Two years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the double-digit rates of growth that made it a local star.
More

Lilly finds solace in new Alzheimer's study

December 17, 2012
J.K. Wall
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
More

Lilly discontinues late-stage trial in rheumatoid arthritis

December 13, 2012
Bloomberg News
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
More

Lilly chief says China too slow in approving new drugs

November 28, 2012
Bloomberg News
China takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
More

Drugmakers collaborate to facilitate drug tests

November 15, 2012
Associated Press
Eli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests of experimental drugs up and running more quickly and efficiently.
More

Life sciences finance pro heading to startupRestricted Content

November 10, 2012
Chris O'Malley
If a biotech startup were akin to a rock band, Kristin Sherman might be the keyboardist. She’s not front-and-center on the stage, but the ballad wouldn’t be as dynamic without her pounding the chords.
More

Lilly continues string of positive trials

October 22, 2012
J.K. Wall
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
More
Page  << 1 2 3 4 5 6 7 8 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am so impressed that the smoking ban FAILED in Kokomo! I might just move to your Awesome city!

  2. way to much breweries being built in indianapolis. its going to be saturated market, if not already. when is enough, enough??

  3. This house is a reminder of Hamilton County history. Its position near the interstate is significant to remember what Hamilton County was before the SUPERBROKERs, Navients, commercial parks, sprawling vinyl villages, and acres of concrete retail showed up. What's truly Wasteful is not reusing a structure that could still be useful. History isn't confined to parks and books.

  4. To compare Connor Prairie or the Zoo to a random old house is a big ridiculous. If it were any where near the level of significance there wouldn't be a major funding gap. Put a big billboard on I-69 funded by the tourism board for people to come visit this old house, and I doubt there would be any takers, since other than age there is no significance whatsoever. Clearly the tax payers of Fishers don't have a significant interest in this project, so PLEASE DON'T USE OUR VALUABLE MONEY. Government money is finite and needs to be utilized for the most efficient and productive purposes. This is far from that.

  5. I only tried it 2x and didn't think much of it both times. With the new apts plus a couple other of new developments on Guilford, I am surprised it didn't get more business. Plus you have a couple of subdivisions across the street from it. I hope Upland can keep it going. Good beer and food plus a neat environment and outdoor seating.

ADVERTISEMENT